-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Rsk2xp7ojzvoA/CF6+EtsQV4G9dkwGxq/BHXkUXpKXcCeKA1m4ytJNMyOZ6U/VyS ZABuqhloVK+PRmOzBR9wHQ== 0000950123-01-504538.txt : 20010723 0000950123-01-504538.hdr.sgml : 20010723 ACCESSION NUMBER: 0000950123-01-504538 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20010720 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ROSETTA INPHARMATICS INC CENTRAL INDEX KEY: 0001081935 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 911770023 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: SEC FILE NUMBER: 005-59447 FILM NUMBER: 1685135 BUSINESS ADDRESS: STREET 1: 12040 115TH AVE NE STREET 2: SUITE 210 CITY: KIRKLAND STATE: WA ZIP: 98034 BUSINESS PHONE: 4258237336 MAIL ADDRESS: STREET 1: 12040 115TH AVENUE NE CITY: KIRKLAND STATE: WA ZIP: 98034 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: MERCK & CO INC CENTRAL INDEX KEY: 0000064978 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 221109110 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: ONE MERCK DR STREET 2: P O BOX 100 CITY: WHITEHOUSE STATION STATE: NJ ZIP: 08889-0100 BUSINESS PHONE: 9084234044 MAIL ADDRESS: STREET 1: ONE MERCK DR STREET 2: PO BOX 100 WS3AB-05 CITY: WHITEHOUSE STATION STATE: NJ ZIP: 08889-0100 SC 13D/A 1 y51518sc13da.txt AMENDMENT NO. 1 TO SCHEDULE 13D 1 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13D-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (AMENDMENT NO. 1) Rosetta Inpharmatics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 777777103 (CUSIP Number) Celia A. Colbert with a copy to: Vice President, Secretary Gary P. Cooperstein and Assistant General Counsel Fried, Frank, Harris, Shriver & Jacobson Merck & Co., Inc. One New York Plaza One Merck Drive New York, NY 10004-1980 Whitehouse Station, (212) 859-8000 New Jersey 08889-0100 (908) 423-1000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) July 19, 2001 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box [ ]. Note: Schedules filed in paper format shall include a signed original and five copies of the Schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent. *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 2 SCHEDULE 13D CUSIP No. 777777103 1 NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON MERCK & CO., INC. - 22-1109110 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) [ ] (b) [ ] NOT APPLICABLE 3 SEC USE ONLY 4 SOURCE OF FUNDS (SEE INSTRUCTIONS) 00, WC 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) [ ] NOT APPLICABLE 6 CITIZENSHIP OR PLACE OF ORGANIZATION NEW JERSEY NUMBER OF 7 SOLE VOTING POWER SHARES SEE ITEM 5 BENEFICIALLY 8 SHARED VOTING POWER OWNED BY SEE ITEM 5 EACH 9 SOLE DISPOSITIVE POWER REPORTING SEE ITEM 5 PERSON 10 SHARED DISPOSITIVE POWER WITH -0- 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON SEE ITEM 5 12 CHECK BOX IF AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES [ ] 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 100% 14 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO 3 This Amendment No. 1 to Schedule 13D (the "Amendment") amends and supplements the Schedule 13D originally filed on May 21, 2001 (the "Schedule 13D") by Merck & Co., Inc., a New Jersey corporation ("Merck"), relating to (i) the merger (the "Merger") of Coho Acquisition Corp., a Delaware corporation and a direct wholly-owned subsidiary of Merck ("Merger Sub") with and into Rosetta Inpharmatics, Inc., a Delaware corporation ("Rosetta"), pursuant to the Agreement and Plan of Merger, dated as of May 10, 2001 between Merck, Merger Sub and Rosetta (the "Merger Agreement") and (ii) certain transactions entered into in connection with the Merger Agreement and described below. Except as amended by this Amendment, there has been no change in the information previously reported on the Schedule 13D. ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION. See Item 5. ITEM 4. PURPOSE OF TRANSACTION. See Item 5. ITEM 5. INTERESTS IN SECURITIES OF THE ISSUER. Item 3, Item 4 and Items 5(a)-(c) are hereby amended and supplemented by the addition of the following information: On July 19, 2001, at the effective time of the Merger (the "Effective Time"), Merger Sub was merged with and into Rosetta and Rosetta became a wholly-owned subsidiary of Merck, pursuant to the terms and conditions of the Merger Agreement. By virtue of the Merger, each share of Rosetta common stock (other than those shares held in the treasury of Rosetta or shares that were owned by Rosetta, Merck or Merger Sub) was converted into the right to receive 0.2352 shares of Merck common stock, and cash in lieu of fractional shares of Merck common stock. By virtue of the Merger, each share of the common stock of Merger Sub, par value $0.01 per share, was converted into one share of the common stock of Rosetta. As a result of the Merger, Merck now beneficially owns 100% of the outstanding shares of Rosetta common stock. As previously described in the Schedule 13D, simultaneously with the execution of the Merger Agreement, Merck and certain stockholders of Rosetta (collectively, the "Stockholders") entered into separate Voting and Stock Option Agreements, dated as of May 10, 2001 (the "Voting and Stock Option Agreements") pursuant to which, among other things, Merck obtained the right, upon the occurrence of certain events, to purchase upon exercise of the option 9,631,035 shares of Rosetta common stock held by the Stockholders, as well as any additional shares of Rosetta common stock acquired by the Stockholders prior to such exercise. Pursuant to the terms of the Voting and Stock Option Agreements, the Voting and Stock Option 3 4 Agreements terminated at the Effective Time. A copy of the form of Voting and Stock Option Agreements was attached to the Schedule 13D and is specifically incorporated herein by reference, and the description herein of the Voting and Stock Option Agreements is qualified in its entirety by reference to such form of Voting and Stock Option Agreements. ITEM 7. MATERIAL TO BE FILED AS EXHIBITS. DOCUMENT Exhibit A - Press Release issued on July 19, 2001. 4 5 SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: July 20, 2001 MERCK & CO., INC. By: /s/ Celia A. Colbert --------------------------------- Name: Celia A. Colbert Title: Vice President, Secretary and Assistant General Counsel 5 6 EXHIBIT INDEX DOCUMENT Exhibit A - Press Release issued July 19, 2001. 6 EX-99.A 2 y51518ex99-a.txt PRESS RELEASE 1 EXHIBIT 99.1 FOR IMMEDIATE RELEASE Press Contact: Gwen Fisher Investor Contact: Laura Jordan (908)423-6154 (908)423-5185 MERCK COMPLETES ACQUISITION OF ROSETTA INPHARMATICS, INC. Whitehouse Station, N.J., July 19, 2001 - Merck & Co., Inc. (NYSE: MRK) announced today that it has completed its acquisition of Rosetta Inpharmatics, Inc. (NASDAQ: RSTA) in a tax-free reorganization. Each share of Rosetta stock has been converted into 0.2352 shares of Merck stock. The transaction has a net equity value of approximately $540 million. To promote the continued success of Rosetta's highly skilled team, Merck will maintain Rosetta as a wholly owned subsidiary, reporting to Anthony Ford-Hutchinson, Ph.D., executive vice president, worldwide basic research, Merck Research Laboratories (MRL). Stephen Friend, M.D., Ph.D., formerly Rosetta's chairman and chief executive officer, will be joining Merck as president of Rosetta, and vice president, basic research, MRL. Merck will keep Rosetta's existing facilities in Kirkland and Bothell, Wash. The organization will continue to operate under the name Rosetta Inpharmatics, Inc. "We're extremely pleased to have Rosetta now as part of Merck Research Laboratories," said Dr. Ford-Hutchinson. "Rosetta will be a tremendous asset in helping Merck more efficiently analyze gene data to predict how medical compounds will interact with different kinds of cells in the body, therefore potentially allowing Merck scientists to more accurately select drug targets and speed up the development process." ABOUT MERCK Merck & Co., Inc. is a leading, research-driven pharmaceutical products and services company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint - more - 2 ventures. Merck-Medco manages pharmacy benefits for employees, insurers and other plan sponsors, encouraging the appropriate use of medicines and providing disease management programs. Through these complementary capabilities, Merck works to improve the quality of life and contain overall health care costs. This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this document should be evaluated together with the many uncertainties that affect our businesses, particularly those mentioned in the cautionary statements in Item 1 of our Form 10-K for the year ended Dec. 31, 2000, and in our periodic reports on Form 10-Q and Form 8-K (if any) which we incorporate by reference. ### -----END PRIVACY-ENHANCED MESSAGE-----